ep io revenu remain
two-fold first believ compani continu face substanti loss
exclus loe especi includ lyrica second
continu believ oncolog platform make progress may
insuffici counter loe headwind continu see necess acquisit
io space
exceed consensu ep expect vs revenu
line expect innov health key growth driver yoy
oper core product eliqui xeljanz prevnar ibranc continu grow
volum eu howev one-tim price adjust due final
reimburs establish price level compar european price analogu
oncolog product neg impact revenu eu believ ibranc
comfort posit despit anticip label expans could come pressur
compet product gain market share label expans note
next gener inhibitor develop ibranc resist patient expect
reach clinic year
expect gener biosimilar competit viagra enbrel
 neg impact innov health revenu importantli face loe
lyrica one main revenu contributor decemb financi
guidanc per compani assum gener competit lyrica
june conting upon six-month patent-term extens grant
fda pediatr exclus compani current pursu revenu
pfe essenti health year declin due larg part expect product
oper growth strong emerg market mainli china pfe biosimilar
portfolio oper mainli driven inflectra
potenti acquisit oncolog
clinic regulatori progress talazoparib xtandi underlin pfe plan
transit oncolog market leader potenti zytiga gener entranc could lead
price pressur xtandi although believ product may
differenti enough cushion immedi impact believ immune-oncolog
area greatest interest compani antibodi bavencio crucial
backbon monotherapi particular combin therapi see exampl inlyta
well combin need leverag develop
degre alreadi approv io platform counteract compani
project neg impact per year
number reiter call call
manag reluct comment differ vs inhibit
emphas develop inhibitor close monitor new
clinic data avail fact find quit interest continu believ
differ inhibit could lead clinic differ see
previou note octob januari
due tax reform plan invest approxim capit project
next year includ strengthen manufactur
plan make contribut pension plan alloc
special one-tim bonu nonexecut employe
new tax measur place anticip adjust effect tax rate approxim
estim may translat effect
ep accord manag tax rate sustain beyond
page analyst certif import disclosur
given favor repatri provis manag current review
capit alloc opportun new tax code continu believ could
includ potenti large-scal acquisit due differ antibodi
import get stronger foothold io space see previou note
manag said call tax reform chang outlook
gener size deal deal would financ
updat estim base perform guidanc
manag commentari earn call ep estim increas
revenu base updat compani guidanc well recent
implement tax reform addit model loe lyrica follow market
entri gener non-gaap sg expens estim
move respect dilut share count reflect
share repurchas program anticip occur per compani
decreas estim effect tax rate well subsequ
year due manag commentari call recent tax reform
valuat risk
valuat fair valu estim base discount cash flow analysi
impli price-to-earnings multipl earn estim assum unchang
termin growth rate wacc revenu model assum gener
competit includ pfe valuabl pipelin asset perspect
predominantli ph risk-adjust basi
downsid risk risk rate estim valuat includ higher-than
anticip oper expens new product launch perform wors
expect lead lower profit pipelin setback may alter futur revenu
assumpt push back launch date increas competit gip voc
landscap particularli oncolog may slow initi demand new product
price new brand product
upsid risk risk upsid includ favor clinic data readout new
product commerci regulatori legal chang favor product
page analyst certif import disclosur
million except per share number
good sold
amort intang asset
compani report guggenheim secur llc estim
page analyst certif import disclosur
